In 2016 the Myotonic Dystrophy Foundation made a grant to RUCDR Infinite Biologics (rebranded as Sampled in 2022) and Rutgers University, which led to the creation of 21 induced pluripotent stem cell lines (iPSCs) from seven subjects for DM1 and DM2.
iPSCs are human-derived cell lines for testing targets against DM and to understand cell changes as the natural history of DM progresses.
These iPSC lines are available through the National Institute of Neurological Disorders and Stroke (NINDS) Human Cell and Data Repository (NHCDR). These cell lines are available for distribution through the NHCDR online catalog to commercial and academic users.
Information regarding these cell lines, subject and clinical data can also be found on the NHCDR website. Questions about the cell lines may be directed to Dr. Jennifer Moore, Director of Stem Cell Services and Technologies at Rutgers University, at firstname.lastname@example.org.